Latest Regulatory News

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

RAS Technology Holdings will not renew its Complete Racing Solution contract with Stake in 2026, shifting focus to expanding in regulated markets and Asia’s burgeoning racing sector.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

Pacgold has secured approval to restart heap leach irrigation at its White Dam Gold Project and is progressing a significant drilling campaign to upgrade resources, setting the stage for a production restart in 2026.

Renergen Limited and ASP Isotopes Inc. have cleared all conditions for their merger scheme, setting the stage for integration and a production update from the Virginia Gas Project early next year.

Cavalier Resources has reported further high-grade gold assay results from its Southern Development Area at the Crawford Gold Project, confirming promising extensional mineralisation beyond the Stage 1 Starter Pit. The company is advancing plans to upgrade its Mineral Resource Estimate while awaiting additional assay data.

Buru Energy is actively pursuing funding for its 2026 drilling campaign to validate resources at the Rafael Gas Project, aiming for a Final Investment Decision in the second half of 2026 and first cashflow by 2028.

FireFly Metals has successfully raised approximately A$139 million through a multi-part equity raising, significantly bolstering its cash reserves to advance its flagship Green Bay Copper-Gold Project in Newfoundland. The company also closed its oversubscribed Share Purchase Plan early, reflecting strong investor demand.

Netwealth Group Limited will compensate members affected by the First Guardian Master Fund collapse with $101 million, impacting its 1H26 profit but aiming to restore member confidence swiftly.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Equus Energy Limited launches a $15 million public offer to fund the acquisition and development of the Equus Gas Project in Western Australia, backed by conditional funding from Alcoa. The project boasts a large independently certified contingent gas resource, positioning the company to address looming supply shortfalls in domestic and LNG markets.

ActivEX Limited has raised $100,000 through a strategic share placement to Business Victor Investments, aiming to accelerate its exploration projects and strengthen working capital.